MyFinsight
Home
Blog
About
Maturities of marketable
securities
$55,250K
(-81.24%↓ Y/Y)
Issuance of common stock
under equity-based...
$1,100K
(194.91%↑ Y/Y)
Net cash provided by
investing activities
$40,678K
(-54.91%↓ Y/Y)
Net cash provided by
financing activities
$1,100K
(194.91%↑ Y/Y)
Canceled cashflow
$14,572K
Net decrease in cash
and cash...
$3,559K
(134.94%↑ Y/Y)
Canceled cashflow
$38,219K
Purchase of marketable
securities
$14,572K
(-92.87%↓ Y/Y)
Equity-based compensation
expense
$8,447K
(-56.14%↓ Y/Y)
Accrued expenses and
other liabilities
$4,209K
(215.54%↑ Y/Y)
Prepaid expenses and
other assets
-$2,088K
(60.30%↑ Y/Y)
Accounts payable
$1,216K
(56.10%↑ Y/Y)
Depreciation and
amortization
$79K
(-48.37%↓ Y/Y)
Net cash used in
operating activities
-$38,219K
(62.07%↑ Y/Y)
Canceled cashflow
$16,039K
Net loss
-$53,704K
(54.70%↑ Y/Y)
Accretion of discount on
marketable securities
-$1,331K
Back
Back
Cash Flow
Cullinan Therapeutics, Inc. (CGEM)
Cullinan Therapeutics, Inc. (CGEM)
source: myfinsight.com